The World Health Organization provides regional and national strategies and operational plans that aim to support countries in work to achieve measles control and elimination. These are guided by high level frameworks including the Immunization Agenda 2030 and the Measles and Rubella Strategic Frame...work 2021–2030. These frameworks promote improvements in routine immunization programmes to reach all children, reduce immunity gaps and prevent outbreaks within the context of universal health care.
This interim guidance on Targeted and selective strategies in measles and rubella vaccination campaigns adds to the suite of guidance documents. It provides expanded description of methods to determine age groups for inclusion in preventive and outbreak response measles and rubella vaccination campaigns; and operational considerations that are specific to targeted and selective strategies in measles and rubella vaccination campaigns. This guidance also updates definitions for tailored, targeted and selective campaigns.The World Health Organization provides regional and national strategies and operational plans that aim to support countries in work to achieve measles control and elimination. These are guided by high level frameworks including the Immunization Agenda 2030 and the Measles and Rubella Strategic Framework 2021–2030. These frameworks promote improvements in routine immunization programmes to reach all children, reduce immunity gaps and prevent outbreaks within the context of universal health care.
This interim guidance on Targeted and selective strategies in measles and rubella vaccination campaigns adds to the suite of guidance documents. It provides expanded description of methods to determine age groups for inclusion in preventive and outbreak response measles and rubella vaccination campaigns; and operational considerations that are specific to targeted and selective strategies in measles and rubella vaccination campaigns. This guidance also updates definitions for tailored, targeted and selective campaigns.
more
As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt...ing a life course approach (LCA) to immunization, vaccination programs can be tailored to close immunity gaps at different stages of life. The life course approach foresees the establishment of multiple strategies to reduce missed opportunities for vaccination according to age group. This technical document explains the key concepts of the LCA with a focus on immunization by vaccination, as well as the underlying biological mechanisms that require the application different vaccines at different life stages according to changes to the immune system and in the epidemiological situation of a community.
more
10 May 2021
This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020.
This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considera...tions on vaccine certificates or “passports” will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.
more
Six maladies évitables par la vaccination ont été incluses dès le
début dans le PEV : la diphtérie, la rougeole, la coqueluche, la
poliomyélite, le tétanos et la tuberculose.
Document d’information scientifique
24 avril 2020
Le développement d’une immunité face à un agent pathogène à la suite d’une infection naturelle comporte plusieurs étapes et prend généralement une à deux semaines. Une infection virale entraîne immédiatement une réponse immunit...aire innée, non spécifique, au cours de laquelle les macrophages, les neutrophiles et les cellules dendritiques ralentissent la progression du virus et peuvent même éviter l’apparition de symptômes. Cette réponse non spécifique est suivie d’une réponse adaptative, au cours de laquelle l’organisme produit des anticorps qui se lient spécifiquement au virus. Ces anticorps sont des protéines appelées immunoglobulines. L’organisme produit également des lymphocytes T qui reconnaissent et éliminent les cellules infectées par le virus. Cette réponse adaptative permet parfois d’éliminer le virus de l’organisme et, si elle est suffisamment forte, d’éviter l’aggravation de la maladie ou la réinfection par le même virus. Ce processus est souvent mesuré par la présence d’anticorps dans le sang.
more
The guide explains how vaccines work and answers your common questions as well as providing up-to-date information on the current approved COVID-19 vaccinations in the UK.
This guide was written in January 2021 and updated in March 2021 and is accurate at the time of publishing. Information will b...e updated as it becomes available.
more
Review
Triccas and Counoupas Pneumonia (2016) 8:18; DOI 10.1186/s41479-016-0020-z
As new variants emerge people are wondering if they should wait until a more efficacious vaccine is available or if they should go ahead and get vaccinated now? Answering your questions on COVID-19 vaccines and variants in this episode of Science in 5 is WHO's Dr Soumya Swaminathan.
The Lancet, Early Online Publication, 11 July 2014
doi:10.1016/S0140-6736(14)60934-X
*Free registration is required to view this article
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
Enfrentando la enfermedad de Alzheimer en los países en desarrollo.
Rev Neuropsiquiatr 80 (2), 2017 (P. 105-110)
Recibido: 03/02/2017 Aceptado: 12/06/2017
Natural immunity against COVID-19
Scientific report 10 May 2021
COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important
to identify sources of variation so that policies can be tailored to different population groups. ...In this paper, we analyze the results from a survey designed and implemented in order to identify early adopters and
laggers in six big cities of Latin America. We find that trust in government and science, accurate knowledge about the value of vaccination and vaccine effects, perceived risk of getting sick, and being a student
increase the odds to get vaccinated. We also identify potential laggers as women and populations between 20 and 35 years old who are not students. We discuss specific strategies to promote vaccination among
these populations groups as well as more general strategies designed to gain trust. These findings are specific to the context of Latin America insofar as the underlying factors associated with the choice to be
vaccinated vary significantly by location and in relation to individual-level factors.
more